Oncotarget

Research Papers:

The long noncoding RNA ANRIL acts as an oncogene and contributes to paclitaxel resistance of lung adenocarcinoma A549 cells

Ran Xu _, Yuqiang Mao, Kuanbing Chen, Wei He, Wenjun Shi and Yun Han

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:39177-39184. https://doi.org/10.18632/oncotarget.16640

Metrics: PDF 1077 views  |   HTML 1365 views  |   ?  


Abstract

Ran Xu1, Yuqiang Mao1, Kuanbing Chen1, Wei He1, Wenjun Shi1 and Yun Han1

1Department of Thoracic Surgery, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China

Correspondence to:

Yun Han, email: hany@sj-hospital.org

Keywords: long noncoding RNA, ANRIL, lung adenocarcinoma, chemotherapy resistance, paclitaxel

Received: February 07, 2017    Accepted: March 04, 2017    Published: March 29, 2017

ABSTRACT

Long non-coding RNAs (lncRNAs) are a family of non-protein-coding RNAs that might affect Lung adenocarcinoma (LAD) chemo-resistance and most of them could be used as biomarkers and therapy targets. However, the potential function of lncRNA ANRIL contributed paclitaxel chemo-resistance in LAD is still unknown. This study aimed to observe the expression of ANRIL in LAD, evaluate its biological role in the resistance of LAD cells to paclitaxel and explore the apoptosis role in the ANRIL associated mechanism. Our results showed that ANRIL functioning as a potential oncogene was up-regulated in LAD, and promoted the acquisition of chemo-resistance in paclitaxel partly through the mitochondrial pathway by modulating the expression of apoptosis-related protein cleaved-PARP and Bcl-2. These findings might improve LAD patients’ paclitaxel treatment and made ANRIL to be a new target for paclitaxel-based chemotherapy in LAD.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 16640